Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.

Docetaxel (Taxotere, Rhône-Poulenc Rorer, Antony, France) is highly effective in the first-line treatment of metastatic breast cancer, achieving an objective response rate of 61% (95% confidence interval, 52% to 69%). This rate of response is seen in patients with poor prognostic factors such as liver metastases and multiple organ involvement. In previously treated metastatic disease, docetaxel is also highly active, with an overall objective response rate of 41% in patients with strictly defined anthracycline-resistant disease. Phase II data suggest that docetaxel is the most active agent yet available in the treatment of advanced breast cancer; this conclusion is now supported by the results of randomized phase III trials. These data justify the further investigation of docetaxel alone and in combination chemotherapy.
AuthorsM E Trudeau
JournalSeminars in oncology (Semin Oncol) Vol. 26 Issue 3 Suppl 8 Pg. 21-6 (Jun 1999) ISSN: 0093-7754 [Print] UNITED STATES
PMID10403470 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • docetaxel
  • Paclitaxel
  • Antineoplastic Agents, Phytogenic (therapeutic use)
  • Breast Neoplasms (drug therapy, pathology)
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Neoplasm Metastasis
  • Paclitaxel (analogs & derivatives, therapeutic use)
  • Randomized Controlled Trials as Topic
  • Taxoids

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: